3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
19
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Heart Failure
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
Carvedilol
3
sacubitril and valsartan sodium hydrate drug combination
2
dapagliflozin
2
pertuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
Trastuzumab
1
Specimen Handling
1
Secondary Prevention
1
Perindopril
1
Ogivri
1
Metoprolol
1
Exercise
1
Electronic Health Records
1
Echocardiography
1
Carnitine
1
Bisoprolol
1
Adrenergic beta-Antagonists
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Heart Failure
×
Ogivri
×
Breast
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled